Back to Journals » International Journal of Nanomedicine » Volume 17
In vitro and in vivo Evaluation of Novel NGR-Modified Liposomes Containing Brucine [Retraction]
Received 17 November 2022
Accepted for publication 17 November 2022
Published 18 November 2022 Volume 2022:17 Pages 5489—5490
Li S, Wang X. Int J Nanomedicine. 2017;12:5797–5804.
The Editor and Publisher of International Journal of Nanomedicine wish to retract the published article. Concerns were raised regarding the alleged duplication of images in Figure 7 with the same images from other unrelated articles. Specifically,
- Figure 7A, Liver appears to have been duplicated with the same image from Figure 5C, Liver from Zhou et al, 2017 (https://doi.org/10.2147/DDDT.S146925) and Figure 4Bc from Li & Gong, 2016 (https://doi.org/10.2147/DDDT.S113670).
- Figure 7A, Spleen appears to have been duplicated with the same image from Figure 5B, Spleen from Zhou et al, 2017 (https://doi.org/10.2147/DDDT.S146925).
- Figure 7B, Spleen appears to have been duplicated with the same image from Figure 5C, Spleen from Zhou et al, 2017 (https://doi.org/10.2147/DDDT.S146925).
The authors did not respond to our queries and no explanation for the alleged image duplication was provided. The Editor requested to retract the article and the authors were notified of this.
We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
This retraction relates to this paper
© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.